Showing results (231-240 of 261) with videos related to

Sort By:
Pageof 27
BMC Chemistry|July 31, 2022
Design, synthesis, and molecular docking studies of diphenylquinoxaline-6-carbohydrazide hybrids as potent α-glucosidase inhibitorsKeyvan Pedrood, Zahra Rezaei, Kimia Khavaninzadeh, et al.
Scientific Reports|August 18, 2022
Design, synthesis, and in silico studies of quinoline-based-benzo[d]imidazole bearing different acetamide derivatives as potent α-glucosidase inhibitorsMilad Noori, Ali Davoodi, Aida Iraji, et al.
Bioorganic & Medicinal Chemistry Letters|January 22, 2019
Design and synthesis of new fused carbazole-imidazole derivatives as anti-diabetic agents: In vitro α-glucosidase inhibition, kinetic, and in silico studiesMehdi Adib, Fariba Peytam, Reihaneh Shourgeshty, et al.
BMC Chemistry|November 16, 2022
Synthesis and bioactivities evaluation of quinazolin-4(3H)-one derivatives as α-glucosidase inhibitorsMahshid Moheb, Aida Iraji, Navid Dastyafteh, et al.
Scientific Reports|February 5, 2025
Cost-reduction strategy to culture patient derived bladder tumor organoidsMahsa Mollapour Sisakht, Fatemeh Gholizadeh, Shirin Hekmatirad, et al.
Scientific Reports|May 15, 2023
Synthesis, in vitro inhibitor screening, structure-activity relationship, and molecular dynamic simulation studies of novel thioquinoline derivatives as potent α-glucosidase inhibitorsRasaDokht Forozan, Minoo Khalili Ghomi, Aida Iraji, et al.
RSC Advances|December 22, 2025
New coumarin-chalcone-triazole hybrids as promising anti-diabetic agents: from molecular design to in vivo validationFariba Peytam, Maryam Norouzbahari, Mahsa Akbari, et al.
Molecular Diversity|March 20, 2020
Design and synthesis of 4,5-diphenyl-imidazol-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic and docking studiesMohammad Sadegh Asgari, Maryam Mohammadi-Khanaposhtani, Zeinab Sharafi, et al.
Scientific Reports|July 31, 2023
Design, synthesis, in vitro, and in silico evaluations of benzo[d]imidazole-amide-1,2,3-triazole-N-arylacetamide hybrids as new antidiabetic agents targeting α-glucosidaseFaeze Yousefnejad, Mahyar Mohammadi-Moghadam-Goozali, Mohammad Hosein Sayahi, et al.
Scientific Reports|September 22, 2023
Imidazo[1,2-c]quinazolines as a novel and potent scaffold of α-glucosidase inhibitors: design, synthesis, biological evaluations, and in silico studiesFariba Peytam, Faezeh Sadat Hosseini, Malak Hekmati, et al.
Pageof 27